Detrimental influences of intraluminally-administered sclerotic agents on surrounding tissues and peripheral nerves: an experimental study.
The minimally-invasive nature of sclerotherapy makes it one of the first treatment options for venous malformations, although treatment-related complications, such as peripheral nerve paralysis, have been reported in some clinical cases. However, no studies of the aetiology of the detrimental effects of intraluminally-administered sclerotic agents on the surrounding tissues, including the peripheral nerves, have yet been published. This study therefore investigated the influences of intraluminally-administered sclerotic agents on the tissues surrounding the injection site using a newly-developed rat femoral vein model. Using this model, the effects of absolute ethanol, 5% ethanolamine oleate, and 1% polidocanol were compared histologically with those of normal saline controls. Fluorescein isothiocyanate-conjugated agents were administered and the leakage of sclerotic agents through the venous wall was evaluated by fluorescence microscopy. Damage to the adjacent femoral nerve was quantitatively evaluated by counting the numbers of axons in cross-sections. All the sclerotic agents caused vascular wall injuries and leakage into the surrounding tissues. The number of axons in the femoral nerve was significantly reduced following administration of absolute ethanol or 5% ethanolamine oleate, compared with normal saline. The results of this study suggest that sclerotic agents commonly leak out the vascular lumen, and some agents can cause adjacent nerve injury. It is important to be aware of this type of complication of sclerotherapy for venous malformations when selecting appropriate therapeutic interventions.
Department of Plastic Surgery, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Masahide
M
Fujiki
Masakazu
M
Kurita
Mine
M
Ozaki
Hayato
H
Kawakami
Nobuyuki
N
Kaji
Akihiko
A
Takushima
Kiyonori
K
Harii
D000818:Animals; D002199:Capillary Permeability; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D000431:Ethanol / Q000008:administration & dosage* / Q000009:adverse effects; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000473:pathology; D005267:Femoral Nerve / Q000187:drug effects* / Q000293:injuries / Q000473:pathology; D005268:Femoral Vein / Q000473:pathology; D016650:Fluorescein-5-isothiocyanate; D007275:Injections, Intravenous; D008855:Microscopy, Electron, Scanning; D009829:Oleic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects*; D015911:Sclerotherapy / Q000009:adverse effects*; D054079:Vascular Malformations / Q000628:therapy
D009829:Oleic Acids; D012597:Sclerosing Solutions; D000077423:Polidocanol; D000431:Ethanol; D011092:Polyethylene Glycols; D016650:Fluorescein-5-isothiocyanate; C033343:ethanolamine oleate